The live-cell encapsulation market is expected to increase with a CAGR of nearly 3.2% during the forecast period. The key factor accrediting to the growth of the live-cell encapsulation market is growing public-private investments to fund product development.

Furthermore, the increasing research programs to establish the clinical efficacy of the cell encapsulation process is boosting the market growth. The rising awareness programs related to the role of live cell encapsulation in the treatment of major chronic diseases like cancers, autoimmune diseases, etc. The live-cell encapsulation is a promising technology in the treatment of neurological disorders, as the drugs that are encapsulated overcome the blood-brain barrier which cannot be achieved by oral drugs. Another disorder, microencapsulation can tackle is type 1 diabetes. In this condition, the beta islet cells of the pancreas are destroyed by the immune system.

So the insulin-producing cells are encapsulated so that the immune system doesn’t destroy them and at the same time letting the encapsulated cells to respond to glucose levels by producing insulin. The encapsulated cell can be used in treating many diseases and the research and development is still in progress. However the high cost of the good quality raw material and adoption of alternative therapies as they are major factors restraining the growth of the market.

Key Market Trends

Drug delivery segment is expected to be the largest contributor to the live cell encapsulation market

Cell encapsulation is used for the manufacturing of effective drug delivery. The advantages of this type of drug delivery are its effectiveness, tolerability, and patient compliance.

Microencapsulation has various substantial advantages as a drug delivery system they are, an encapsulated live cells against degradation or destruction by the immune system. It precisely control the release rate of an fused drug over periods (hours to months), an easy administration, pre-programmed drug-release profiles which tally the therapeutic requirements of the patient. The major factor driving the segment of the market is increasing public-private investments and fundings for the development of drug delivery systems.

North America is one of the major income-generating regions in the live cell encapsulation market

North America is expected to dominate the overall live-cell encapsulation market, throughout the forecast period. The market growth is due to factors such as the presence of key players, increasing per capita healthcare expenditure, increasing funding and investment for research and development programs in the United States and Canada, established healthcare infrastructure are the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and the heavy adoption of new technology in the region are some of the drivers expected to increase market growth.

Competitive Landscape

As per the scope of the report, live-cell encapsulation market is relatively competitive and consists of several major players. Some of the companies which are currently dominating the market are Viacyte, Inc, Living Cell Technologies Limited., Diatranz Otsuka Ltd, PharmaCyte Biotech Inc., Sernova Corporation, Sigilon Therapeutics, Inc., B?CHI Labortechnik AG, Blacktrace Holdings Ltd.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support